HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Tyra Biosciences (NASDAQ:TYRA) and maintained a price target of $23.
June 05, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Tyra Biosciences and maintained a price target of $23.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100